NCT07337967

Brief Summary

Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
13mo left

Started Jan 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
Jan 2026Sep 2027

First Submitted

Initial submission to the registry

December 13, 2025

Completed
19 days until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 13, 2026

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

January 13, 2026

Status Verified

December 1, 2025

Enrollment Period

1.1 years

First QC Date

December 13, 2025

Last Update Submit

January 7, 2026

Conditions

B Chronic Lymphocytic Leukemia

Outcome Measures

Primary Outcomes (3)

  • Reticulocyte count

    Absolute peripheral blood reticulocyte count measured in patients with chronic B-cell lymphoproliferative disorders (CLPDs). Unit of Measure: ×10⁹/L

    1 year

  • Reticulocyte percentage

    Percentage of reticulocytes among total red blood cells in peripheral blood of patients with CLPDs. Unit of Measure: %

    1 year

  • Immature reticulocyte fraction (IRF)

    Proportion of immature reticulocytes in peripheral blood measured in patients with CLPDs. Unit of Measure: %

    1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.

You may qualify if:

  • \- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.

You may not qualify if:

  • \) Patients received chemotherapy.
  • Patients with Active bleeding
  • Patients with recent blood transfusion (less than 2 weeks).
  • Patients on haematinics or vitamin B 12 therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Leukemia, B-Cell

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

December 13, 2025

First Posted

January 13, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

January 13, 2026

Record last verified: 2025-12